Pharma Europe 2016: Reviewing drug package inserts available in UAE for FDA recommended pharmacogenomic information - Anoop K Agarwal - Gulf Medical University

Anoop K Agarwal
Gulf Medical University, UAE

Pharmacogenomics aims to characterize the contribution of genetic polymorphisms to variability in drug response and toxicity. FDA has issued a list of drugs which exhibit polymorphism and relevant sections for providing pharmacogenomic information and their biomarkers to reduce the risk of drug toxicity. The objective of the study was to review the package insert for the presence and extent of pharmacogenomic information as per FDA recommendations. A total of 67 Package inserts of 41 drugs in different therapeutic areas available in UAE under various brand names were thoroughly reviewed for direct and indirect information signifying polymorphism. The description of serious drug-drug interaction and its management was also reviewed for risk assessment. The type of pharmacogenomic biomarker and related toxicity mentioned under different labeling sections was compared. Only 26 package inserts of 17 drugs (41%) prescribed for treating cancer, cardiovascular, CNS and Gastrointestinal disorders provided direct genetic evidence and information on the type of polymorphism influencing drug efficacy and toxicity. Indirect indicators describing genetic variation in metabolizing enzyme activity was present in 20 inserts (30%). Though rare adverse reactions had been mentioned under warning and contraindications, no special reference to genomic cause was identified. The FDA recommended pharmacogenomic information was lacking in 59% package inserts available in UAE. This information needs to be incorporated to enhance patient safety and awareness. Pharmacogenomics is the investigation of the job of the genome in sedate reaction. Its name (pharmaco-+ genomics) mirrors its consolidating of pharmacology and genomics. Pharmacogenomics examines how the hereditary cosmetics of an individual influences his/her reaction to drugs. It manages the impact of procured and acquired hereditary minor departure from sedate reaction in patients by relating quality articulation or single-nucleotide polymorphisms with pharmacokinetics (medicate ingestion, dissemination, digestion, and disposal) and pharmacodynamics (impacts interceded through a medication's natural target). The term pharmacogenomics is regularly utilized conversely with pharmacogenetics. Albite the two terms identify with medicate reaction dependent on hereditary impacts, pharmacogenetics centers around single medication quality collaborations, while pharmacogenomics includes a more genome-wide affiliation approach, fusing genomics and epigenetics while managing the impacts of different qualities on tranquilize response. Pharmacogenomics plans to create sound intends to enhance sedate treatment, as for the patients' genotype, to guarantee most extreme productivity with insignificant unfriendly effects. Through the use of pharmacogenomics, it is trusted that pharmaceutical medication medicines can veer off based on what is named as the “one-portion fits-all” approach. Pharmacogenomics additionally endeavors to take out the experimentation technique for recommending, permitting doctors to think about their patient's qualities, the usefulness of these qualities, and how this may influence the viability of the patient's present or future medicines (and where relevant, give a clarification to the disappointment of past treatments). Such methodologies guarantee the coming of exactness medication and even customized medication, in which medications and medication blends are improved for tight subsets of patients or in any event, for every individual's one of a kind hereditary makeup. Whether used to clarify a patient's reaction or scarcity in that department to a treatment, or go about as a prescient instrument, it would like to accomplish better treatment results, more prominent adequacy, minimization of the event of medication poison levels and antagonistic medication responses (ADRs). For patients who have absence of remedial reaction to a treatment, elective treatments can be recommended that would best suit their prerequisites. So as to give pharmacogenomic proposals to a given medication, two potential sorts of info can be utilized: genotyping or exome or entire genome sequencing. Sequencing gives a lot more information focuses, including recognition of changes that rashly end or exome or entire genome sequencing. Sequencing gives a lot more information focuses, including recognition of changes that rashly end or exome or entire genome sequencing. Sequencing gives a lot more information focuses, including recognition of changes that rashly end or exome or entire genome sequencing. Sequencing gives a lot more information focuses, including recognition of changes that rashly end.

This work is partly presented at 5th Annual European Pharma Congress July 18-20, 2016 held at Berlin, Germany
engaged by the United States Congress to uphold the Federal Food, Drug, and Cosmetic Act, which fills in as the essential concentration for the Agency; the FDA additionally implements different laws, prominently Section 361 of the Public Health Service Act and related guidelines, a large number of which are not legitimately identified with food or medications. These incorporate directing lasers, phones, condoms and control of ailment on items going from certain family unit pets to sperm gift for helped proliferation.

Biography

Anoop K Agarwal completed his PhD in 1988 from Postgraduate Institute of Medical Education and Research, Chandigarh, India. He has 27 years of experience in Pharmacology teaching and research. He is currently the Associate Dean of College of Graduate Studies at Gulf Medical University, Ajman, UAE. He has published more than 50 papers in reputed journals apart from having presented his work in several national and international conferences. He has also been a resource person in several Pharmacology workshops and seminars.

agarwalakdr@gmail.com

This work is partly presented at 5th Annual European Pharma Congress July 18-20, 2016 held at Berlin, Germany